Crossmark

N-Acetylgalactosamine-Conjugated Antisense Oligonucleotides Designed as Inhibitors of ABCB1: Coping with Multidrug Resistance in Hepatocellular Carcinoma

Crossref DOI link: https://doi.org/10.1134/S0026893324060050

Published Online: 2024-12-18

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hasturk, B. https://orcid.org/0000-0001-8790-144X
Avsar, T. https://orcid.org/0000-0001-8841-4811
Ozbas, S. https://orcid.org/0000-0002-1721-7543
Yilmaz, B. Karademir https://orcid.org/0000-0003-1762-0284
Eren, F. https://orcid.org/0000-0001-8126-2413
License Information

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-12-01
More Information

Article History

Received: 28 March 2024

Revised: 17 July 2024

Accepted: 26 July 2024

First Online: 18 December 2024

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

: The study utilized with a commercial cell line (Hep G2 [HEPG2], ATCC HB-8065). As this was an in vitro study, ethical approval and informed consent were not required.

: The authors of this work declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below